# US 2008/0077025 A1 · Methods for determining how to treat congestive heart failure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0077025 A1
- Document ID: US20080077025A1
- Status: Published application
- Kind: A1
- Application number: 11/456,741
- Filed: 2006-07-11
- Published: 2008-03-27
- Earliest claimed: 2005-07-11
- Inventors: Leticia Delgado-Herrera; Robert J. Padley; Jeffrey E. Salon; Roopal B. Thakkar; Bidan Huang
- Web page: https://patentgrep.com/patent/US20080077025A1

## CPC

- A61B 5/021: Measuring pressure in heart or blood vessels
- A61K 31/50: Pyridazines; Hydrogenated pyridazines
- G06Q 30/0217: involving input on products or services in exchange for incentives or rewards
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G06Q: INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present invention relates to methods for determining how to treat congestive heart failure.

## Claims

### Claim 1

A method of predicting an improved clinical outcome in a patient diagnosed with congestive heart failure, the method comprising the steps of:
(a) obtaining a systolic blood pressure, diastolic blood pressure or mean arterial pressure from a patient;
(b) determining whether the systolic blood pressure, diastolic blood pressure or mean arterial pressure of said patient fits at least one predetermined criterion showing a likelihood of an improved clinical outcome; and
(e) predicting said improved clinical outcome based upon the determination in step (b).

### Claim 2 (depends on 1)

The method of claim 1 wherein the predetermined criterion showing a likelihood of improved clinical outcome is a systolic blood pressure less than, equal to or greater, than about 100 mmHg.

### Claim 3 (depends on 1)

The method of claim 1 wherein the predetermined criterion showing a likelihood of improved clinical outcome is a diastolic blood pressure less than, equal to or greater than about 60 mmHg.

### Claim 4 (depends on 1)

The method of claim 1 wherein the predetermined criterion showing a likelihood of improved clinical outcome is a mean arterial pressure less than, equal to or greater than about 75 mmHg.

### Claim 5 (depends on 1)

The method of claim 1 wherein the patient is suffering from acutely decompensated congestive heart failure.

### Claim 6 (depends on 1)

The method of claim 1 wherein a systolic blood pressure equal to or greater than about 100 mmHg indicates an increased likelihood of an improved clinical outcome.

### Claim 7 (depends on 1)

The method of claim 1 wherein a systolic blood pressure less than about 100 mmHg indicates a decreased likelihood of an improved clinical outcome.

### Claim 8

A method for determining whether or not to begin a course of monotherapy with an inotropic drug or a vasodilator in a patient diagnosed with congestive heart failure, the method comprising the steps of:
(a) obtaining a systolic blood pressure, diastolic blood pressure or mean arterial pressure from a patient;
(b) analyzing the systolic blood pressure, diastolic blood pressure or mean arterial pressure of said patient to determine whether said blood pressure, diastolic blood pressure or mean diastolic blood pressure fits at least one predetermined criterion; and
(c) determining whether to begin a course of monotherapy in the patient based upon the analysis in step (b).

### Claim 9 (depends on 8)

The method of claim 8 wherein the predetermined criterion is a systolic blood pressure less than, equal to or greater than about 100 mmHg.

### Claim 10 (depends on 8)

The method of claim 8 wherein the predetermined criterion is a diastolic blood pressure less than, equal to or greater than about 60 mmHg.

### Claim 11 (depends on 8)

The method of claim 8 wherein the predetermined criterion is a mean arterial pressure less than, equal to or greater than about 75 mmHg.

### Claim 12 (depends on 8)

The method of claim 8 wherein in step (c), a determination is made not to begin a course of monotherapy with an inotropic drug or a vasodilator because the patient was determined to have a systolic blood pressure less than about 100 mmHg in step (b).

### Claim 13 (depends on 8)

The method of claim 8 wherein in step (c), a determination is made to begin a course of monotherapy with an inotropic drug or a vasodilator because the patient was determined to have a systolic blood pressure about equal to or greater than about 100 mmHg in step (b).

### Claim 14 (depends on 8, 13)

The method of claims 8 or 13 further comprising the step of administering an effective amount of an inotropic drug or a vasodilator to the patient based upon the determination in step (c).

### Claim 15 (depends on 14)

The method of claim 14 wherein the inotropic drug or vasodilator is administered to the patient orally, buccally, intravenously, intramuscularly, subcutaneously or by inhalation.

### Claim 16 (depends on 14)

The method of claim 14 wherein the inotropic drug is levosimendan, dopamine, dobutamine, inamrinone, milrinone, dopexamine or digoxin.

### Claim 17 (depends on 14)

The method of claim 14 wherein the vasodilator is hydralazine, hydralazine hydrochloride, nicorandil, fenoldopam, natriuretic peptides, natrecor, nesiritide, nitroprusside, nitroprusside sodium, nipride, milrinone, primacor, nitroglycerin, glyceryl trinitrate, isosorbide dinitrate or isosorbide mononitrate.

### Claim 18 (depends on 8)

The method of claim 8 wherein the patient is suffering from acutely decompensated congestive heart failure.

### Claim 19

A method for determining whether or not to begin a course of combination therapy with at least one inotropic drug, at least one vasodilator or combinations thereof in a patient diagnosed with congestive heart failure, the method comprising the steps of:
(a) obtaining a systolic blood pressure, diastolic blood pressure or mean arterial pressure from a patient;
(b) analyzing the systolic blood pressure, diastolic blood pressure or mean arterial pressure of said patient to determine whether said blood pressure, diastolic blood pressure or mean diastolic blood pressure fits at least one predetermined criterion; and
(c) determining whether to begin a course of combination therapy with at least one inotropic drug, at least one vasodilator or combinations thereof in the patient based upon the analysis in step (b).

### Claim 20 (depends on 19)

The method of claim 19 wherein the predetermined criterion is a systolic blood pressure less than, equal to or greater than about 100 mmHg.

### Claim 21 (depends on 19)

The method of claim 19 wherein the predetermined criterion is a diastolic blood pressure less than, equal to or greater than about 60 mmHg.

### Claim 22 (depends on 19)

The method of claim 19 wherein the predetermined criterion is a mean arterial pressure less than, equal to or greater than about 75 mmHg.

### Claim 23 (depends on 19)

The method of claim 19 wherein in step (c), a determination is made not to begin a course of combination therapy with at least one inotropic drug, at least one vasodilator or combinations thereof because the patient was determined to have a systolic blood pressure less than about 100 mmHg in step (b).

### Claim 24 (depends on 19)

The method of claim 19 wherein in step (c), a determination is made to begin a course of combination therapy with at least one inotropic drug, at least one a vasodilator or combinations thereof because the patient was determined to have a systolic blood pressure equal to or greater than about 100 mmHg in step (b).

### Claim 25 (depends on 19, 24)

The method of claims 19 or 24 further comprising the step of administering an effective amount at least one inotropic drug, at least one vasodilator or combinations thereof to the patient based upon the determination in step (c).

### Claim 26 (depends on 25)

The method of claim 25 wherein the at least one inotropic drug, at least one vasodilator or combinations thereof is administered to the patient orally, buccally, intravenously, intramuscularly, subcutaneously or by inhalation.

### Claim 27 (depends on 25)

The method of claim 25 wherein the inotropic drug is levosimendan, dopamine, dobutamine, inamrinone, milrinone, dopexamine or digoxin.

### Claim 28 (depends on 25)

The method of claim 25 wherein the vasodilator is hydralazine, hydralazine hydrochloride, nicorandil, fenoldopam, natriuretic peptides, natrecor, nesiritide, nitroprusside, nitroprusside sodium, nipride, milrinone, primacor, nitroglycerin, glyceryl trinitrate, isosorbide dinitrate or isosorbide mononitrate.

### Claim 29 (depends on 19)

The method of claim 19 wherein the patient is suffering from acutely decompensated congestive heart failure.

### Claim 30

A method for determining whether to continue or discontinue a course of monotherapy in a patient diagnosed with congestive heart failure wherein said patient is currently being treated with an inotropic drug or a vasodilator, the method comprising the steps of:
(a) obtaining a systolic blood pressure, diastolic blood pressure or mean arterial pressure from a patient;
(b) analyzing the systolic blood pressure, diastolic blood pressure or mean arterial pressure of said patient to determine whether said systolic blood pressure, diastolic blood pressure or mean diastolic blood pressure fits at least one predetermined criterion; and
(c) determining whether to continue or discontinue the course of monotherapy with the inotropic drug or vasodilator in said patient based upon the analysis in step (b).

### Claim 31 (depends on 30)

The method of claim 30 wherein the predetermined criterion is a systolic blood pressure less than, equal to or greater than about 100 mmHg.

### Claim 32 (depends on 30)

The method of claim 30 wherein the predetermined criterion is a diastolic blood pressure less than, equal to or greater than about 60 mmHg.

### Claim 33 (depends on 30)

The method of claim 30 wherein the predetermined criterion is a mean arterial pressure less than, equal to or greater than about 75 mmHg.

### Claim 34 (depends on 30)

The method of claim 30 wherein in step (c), a determination is made not to continue a course of monotherapy because the patient was determined to have a systolic blood pressure less than about 100 mmHg in step (b).

### Claim 35 (depends on 30)

The method of claim 30 wherein in step (c), a determination is made to continue a course of monotherapy because the patient was determined to have a systolic blood pressure equal to or greater than about 100 mmHg in step (b).

### Claim 36 (depends on 30)

The method of claim 30 wherein the inotropic drug is levosimendan, dopamine, dobutamine, inamrinone, milrinone, dopexamine or digoxin.

### Claim 37 (depends on 30)

The method of claim 30 wherein the vasodilator is hydralazine, hydralazine hydrochloride, nicorandil, fenoldopam, natriuretic peptides, natrecor, nesiritide, nitroprusside, nitroprusside sodium, nipride, milrinone, primacor, nitroglycerin, glyceryl trinitrate, isosorbide dinitrate or isosorbide mononitrate.

### Claim 38 (depends on 30)

The method of claim 30 wherein the patient is suffering from acutely decompensated congestive heart failure.

### Claim 39

A method for determining whether to continue or discontinue a course of combination therapy in a patient diagnosed with congestive heart failure wherein said patient is currently being treated with a combination of at least one inotropic drug, at least one vasodilator or combinations thereof the method comprising the steps of:
(a) obtaining a systolic blood pressure, diastolic blood pressure or a mean arterial pressure from a patient;
(b) analyzing the systolic blood pressure, diastolic blood pressure or mean arterial pressure of said patient to determine whether said systolic blood pressure, diastolic blood pressure or mean diastolic blood pressure fits at least one predetermined criterion; and
(c) determining whether to continue or discontinue the course of combination therapy with the at least one inotropic drug, at least one vasodilator or combinations thereof in said patient based upon the analysis in step (b).

### Claim 40 (depends on 39)

The method of claim 39 wherein the predetermined criterion is a systolic blood pressure less than, equal to or greater than about 100 mmHg.

### Claim 41 (depends on 39)

The method of claim 39 wherein the predetermined criterion is a diastolic blood pressure less than, equal to or greater than about 60 mmHg.

### Claim 42 (depends on 39)

The method of claim 39 wherein the predetermined criterion is a mean arterial pressure less than, equal to or greater than about 75 mmHg.

### Claim 43 (depends on 39)

The method of claim 39 wherein in step (c), a determination is made not to continue a course of combination therapy because the patient was determined to have a systolic blood pressure less than about 100 nm mg in step (b).

### Claim 44 (depends on 39)

The method of claim 39 wherein in step (c), a determination is made to continue a course of combination therapy because the patient was determined to have a systolic blood pressure equal to or greater than about 100 mmHg in step (b).

### Claim 45 (depends on 40)

The method of claim 40 wherein the inotropic drug is levosimendan, dopamine, dobutamine, inamrinone, milrinone, dopexamine or digoxin.

### Claim 46 (depends on 40)

The method of claim 40 wherein the vasodilator is hydralazine, hydralazine hydrochloride, nicorandil, fenoldopam, natriuretic peptides, natrecor, nesiritide, nitroprusside, nitroprusside sodium, nipride, milrinone, primacor, nitroglycerin, glyceryl trinitrate, isosorbide dinitrate or isosorbide mononitrate.

### Claim 47 (depends on 40)

The method of claim 40 wherein the patient is suffering from acutely decompensated congestive heart failure.

### Claim 48

A method of optimizing an existing drug treatment regimen in a patient diagnosed with congestive heart failure and receiving at least one inotropic drug, at least one vasodilator, at least one beta-blocker or combinations thereof, the method comprising the steps of:
(a) obtaining a systolic blood pressure, diastolic blood pressure or mean arterial pressure from a patient;
(b) analyzing the systolic blood pressure, diastolic blood pressure or mean arterial pressure of said patient to determine whether said systolic blood pressure, diastolic blood pressure or mean diastolic blood pressure fits at least one predetermined criterion; and
(c) optimizing the treatment regimen in the patient based upon the analysis in step (b).

### Claim 49 (depends on 48)

The method of claim 48 wherein the predetermined criterion is a systolic blood pressure less than, equal to or greater than about 100 mmHg.

### Claim 50 (depends on 48)

The method of claim 48 wherein the predetermined criterion is a diastolic blood pressure less than, equal to or greater than about 60 mmHg.

### Claim 51 (depends on 48)

The method of claim 48 wherein the predetermined criterion is a mean arterial pressure less than, equal to or greater than about 75 mmHg.

### Claim 52 (depends on 48)

The method of claim 48 wherein in step (c), a determination is made to optimize the treatment regimen by discontinuing the treatment of the patient with at least one inotropic drug, at least one vasodilator, at least one beta-blocker or combinations thereof based upon the determination in step (b) that the patient has a systolic blood pressure less than about 100 mmHg.

### Claim 53 (depends on 48)

The method of claim 48 wherein in step (c), the treatment regimen is optimized by substituting an effective amount of at least one different inotropic drug, at least one different vasodilator, at least one different beta-blocker or different combinations thereof that are not currently being used in the existing treatment regimen for at least one inotropic drug, at least one vasodilator, at least one beta-blocker or combinations thereof that is currently being used in the existing treatment regimen based upon the determination in step (b) that the patient has a systolic blood pressure about equal to or greater than about 100 mmHg.

### Claim 54 (depends on 48)

The method of claim 48 wherein in step (c), the treatment regimen is optimized by adding an effective amount of at least one inotropic drug, at least one vasodilator, at least one beta-blocker or combinations thereof that are not currently being used in the existing treatment regimen based upon the determination in step (b) that the patient has a systolic blood pressure about equal to or greater than about 100 mmHg.

### Claim 55 (depends on 52, 53, 54)

The method of claims 52, 53 or 54 wherein the inotropic drug is levosimendan, dopamine, dobutamine, inamrinone, milrinone, dopexamine or digoxin.

### Claim 56 (depends on 52, 53, 54)

The method of claims 52, 53 or 54 wherein the vasodilator is hydralazine, hydralazine hydrochloride, nicorandil, fenoldopam, natriuretic peptides, natrecor; nesiritide, nitroprusside, nitroprusside sodium, nipride, milrinone, primacor, nitroglycerin, glyceryl trinitrate, isosorbide dinitrate or isosorbide mononitrate.

### Claim 57 (depends on 52, 53, 54)

The methods of claims 52, 53 or 54 wherein the beta-blocker is labetalol, carvedilol, atenolol, esmolol, esmolol hydrochloride, metoprolol, metoprolol succinate, metoprolol tartrate, bisoprolol fumarate, bisoprolol, propranolol or propranolol hydrochloride.

### Claim 58 (depends on 48)

The method of claim 48 wherein the patient is suffering from acutely decompensated congestive heart failure.

### Claim 59 (depends on 1, 8, 19, 30, 39, 48)

A pharmaceutical drug product comprising:
(a) a pharmaceutical drug for the treatment of congestive heart failure in a pharmaceutically-acceptable form for administration to a human, and
(b) printed media or labeling accompanying said pharmaceutical drug in said pharmaceutically acceptable form, wherein said printed media or labeling discloses the method as in any one of claims 1, 8, 19, 30, 39 or 48.

### Claim 60 (depends on 1, 8, 19, 30)

A pharmaceutical drug product comprising:
(a) levosimendan in a pharmaceutically-acceptable form for administration to a human, and
(b) printed media or labeling accompanying said levosimendan, wherein said printed media or labeling discloses the method as in any one of claims 1, 8, 19, 30 39 or 48.

### Claim 61 (depends on 1, 8, 19, 30, 39, 48)

A business method comprising, providing a drug for the treatment of congestive heart failure in a pharmaceutically-acceptable form for administration to a human, and
encouraging a decision maker to refer to printed or electronic media disclosing a method as in any one of claims 1, 8, 19, 30, 39 or 48.

### Claim 62 (depends on 1, 8, 19, 30, 39, 48)

A business method comprising, providing levosimendan in a pharmaceutically-acceptable form for administration to a human, and encouraging a decision maker to refer to printed or electronic media disclosing a method as in any one of claims 1, 8, 19, 30, 39 or 48.

### Claim 63 (depends on 1, 8, 19, 30, 39, 48)

A method of promoting the sale or use of a drug for the treatment of congestive heart failure, the method comprising:
(a) providing said drug in a pharmaceutically-acceptable form for administration to a human, and
(b) providing a customer with printed, graphic, or electronic media disclosing a method as in any one of claims 1, 8, 19, 30, 39 or 48.

### Claim 64 (depends on 1, 8, 19, 30, 39, 48)

A method of promoting the sale or use of levosimendan, the method comprising:
(a) providing said levosimendan in a pharmaceutically-acceptable form for administration to a human, and
(b) providing a customer with printed, graphic, or electronic media disclosing a method as in any one of claims 1, 8, 19, 30, 39 or 48.
